CoChat

Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial

Morabbi, Mohammad-Javad, Razaghi, Emran, Moazen-Zadeh, Ehsan, Safi-Aghdam, Hamideh, Zarrindast, Mohamad R., Vousoghi, Nasim, Akhondzadeh, Shahin · 2018 · International Clinical Psychopharmacology

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

We assessed the efficacy of pexacerfont, a CRF1 antagonist, for the treatment of withdrawal symptoms. In this randomized, double-blind, placebo-controlled clinical trial, male patients with amphetamine or opioid dependence, on the basis of the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR), in the age range 18-55 years, received either pexacerfont or placebo (300, 200, and 100 mg/day in the first, second, and third week, respectively). No antidepressants, behavioral interventions, or substitution therapy were administered. Candidates were excluded if they had DSM-IV-TR axis I or II disorders (other than depressive/anxiety disorders). The primary outcomes were difference in the distribution of positive urine test results for heroin and methamphetamine at the end of the trial, and the mean difference in the change in the Visual Analog Scale (VAS) score for craving from the baseline to the endpoint between the two groups. No significant difference was detected for urine test results, but a significant difference was observed for craving scores. Also, significant time×treatment interactions were found for all the scales including VAS craving, VAS temptation severity, frequency of temptation, Clinical Opiate Withdrawal Scale, Amphetamine Withdrawal Questionnaire, Beck Anxiety Inventory, and Beck Depression Inventory II. Our findings favor pexacerfont as a potential treatment for withdrawal from drug dependence; however, further comprehensive studies are warranted.

Overview

Integrity signals

Registry

Crossref · 10.1097/yic.0000000000000200

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Amiri, 2014, Iran J Psychiatry, 9, 142

Cited by

See all 32

Metadata

Authors
Morabbi, M.-J., Razaghi, E., Moazen-Zadeh, E., Safi-Aghdam, H., Zarrindast, M. R., Vousoghi, N., & Akhondzadeh, S.
Affiliations
Roozbeh Hospital (IR)
Corresponding author
  • Morabbi, Mohammad-Javad
  • Razaghi, Emran
Venue
International Clinical Psychopharmacology
Published
2018-03
Volume
33
Issue
2
Pages
111-119
ISSN
0268-1315 (ISSN-L)
OpenAlex
W2765215453
Cited by
32
References
29
Citations by year
2026: 2 · 2025: 2 · 2024: 7 · 2023: 1 · 2022: 1 · 2021: 5 · 2020: 8 · 2019: 4 · 2018: 2
FWCI
3.61
Type
journal article
Language
en
Open access
closed
Locations
  • International Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
CRF1 receptor antagonist, heroin addiction, methamphetamine dependence, drug withdrawal symptoms, craving, opioid withdrawal, amphetamine withdrawal, anxiety, depression
MeSH terms
CRF Receptor, Type 1, Adult, Central Nervous System Stimulants, Heroin, Double-Blind Method, Humans, Male, Methamphetamine, Middle Aged, Psychiatric Status Rating Scales, Pyrazoles, Severity of Illness Index, Substance Withdrawal Syndrome, Triazines, Substance Abuse Detection, Treatment Outcome, Drug Monitoring, Receptors, Corticotropin-Releasing Hormone, Substance-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders, Visual Analog Scale

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1097/yic.0000000000000200
The paper
Morabbi, M.-J., Razaghi, E., Moazen-Zadeh, E., Safi-Aghdam, H., Zarrindast, M. R., Vousoghi, N., & Akhondzadeh, S. (2018). Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.